375:) to the FDA for Velcade for previously untreated multiple myeloma. The sNDA submitted to the FDA for this indication included data from the Phase III VISTA study, a large, well-controlled international clinical trial, comparing a Velcade-based regimen to a traditional standard of care. Priority review was granted by the FDA in January 2008. On June 20, 2008, the FDA approved VELCADE in combination for patients with previously untreated multiple myeloma. This means that Millennium can market Velcade to patients who have not had any prior therapies for multiple myeloma (a first-line therapy).
33:
329:(alemtuzumab) Injection, and additional investigational drugs in clinical trials. In 2000, a merger with Cambridge Discovery Chemistry gave Millennium a strong presence in the United Kingdom and added to the organization more than 100 scientists with expertise in chemistry. In a strategic business decision, Campath was later sold to the Millennium partner for the drug, ILEX Oncology, which in turn was acquired by
506:
Velcade is the first oncology drug marketed and promoted by
Millennium. Velcade was granted FDA approval little more than four and a half years after initiation of the first clinical trial. To discover and develop such treatments, the Company focuses on key molecular pathways that play crucial roles
336:
In
February 2002, there was a further merger with COR Therapeutics—among the largest such mergers in the history of the biotech industry at that time. In addition to creating a strong pipeline of novel therapeutics, the merger added cardiovascular research and drug development to the company's other
522:
of
Velcade in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Takeda and Ortho Biotech. are co- promoting Velcade in the U.S. Approved in 85
321:
Millennium was founded by Mark J. Levin, CEO, in
Cambridge, Massachusetts in 1993. In its early years, Millennium focused on building science and business teams. Beginning in 1994, Millennium created more than 20 strategic alliances with pharmaceutical and biotechnology companies. These alliances
378:
In May 2008, Takeda
Pharmaceutical Company Limited purchased Millennium for $ 8.8 billion. Millennium was operating as an independent subsidiary, serving as the global center of excellence in oncology under its new name: "Millennium: The Takeda Oncology Company". This global footprint includes
386:
In
October 2023, Takeda began the process of withdrawing its drug, Exkivity in the United States after ending a trial for the drug early due to failure in the late-stage study. Exkivity is a drug for adults with non-small cell lung cancer. The FDA granted approval for the trial in 2021.
308:
On May 14, 2008, Japanese company Takeda
Pharmaceutical announced the completion of its acquisition of Millennium for US$ 25.00 per share in cash—a deal worth $ 8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger as a wholly owned subsidiary
285:
to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.
379:
oncology research and marketing strategy and oversight. In addition to
Cambridge, MA, oncology resources include facilities in San Diego, San Francisco, Tsukuba and Osaka with Millennium as the global hub for this critical and rapidly expanding therapeutic area.
382:
In 2014, Takeda dropped the "Millennium" brand; effectively renaming the subsidiary into Takeda
Oncology. However, Millennium Pharmaceuticals Inc is still a legal holding of Takeda and its name is still used for on-going legal processes.
912:
511:. Takeda Oncology applies this approach broadly throughout its R&D program to develop novel treatments not just for cancer but also for a number of other important diseases.
364:(FDA) granted approval for the treatment of multiple myeloma for patients who had not responded to at least two other therapies for the disease. Velcade — the first FDA-approved
353:
on the development and marketing of
Integrilin until 2005 when Millennium licensed the exclusive U.S. commercialization and development rights of Integrilin to Schering-Plough.
839:
480:
Seattle Genetics is responsible for commercialization of ADCETRIS in the United States, and Takeda Oncology is responsible in Europe and the rest of the world.
985:
990:
980:
975:
426:
Velcade is indicated for the front-line treatment of multiple myeloma and for patients with mantle cell lymphoma who have received at least 1 prior therapy.
995:
970:
368:
inhibitor — reached the market in record time and represented the first treatment in more than a decade to be approved for patients with multiple myeloma.
1010:
453:
Mifamurtide is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in about a third of cases.
866:
641:
617:
812:
739:
361:
665:
17:
786:
1015:
1005:
97:
69:
1020:
689:
913:"U.S. FDA Approves Takeda's NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma"
715:
76:
322:
provided Millennium with close to $ 2 billion of committed funding that was used to develop and enhance its pipeline.
761:
474:
Adcetris is an antibody-drug conjugate approved to treat anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.
116:
50:
1000:
507:
in underlying disease processes, and on identifying therapeutically significant differences that may exist among
83:
54:
955:
223:
945:
65:
440:
Family of Companies, are responsible for commercialization of VELCADE in Europe and the rest of the world.
740:"VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone"
255:
346:
43:
152:
371:
In late December 2007, Millennium successfully submitted a supplemental new drug application (
263:
90:
515:
437:
544:
8:
891:
469:
867:"Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop"
337:
key therapeutic areas: oncology and inflammation. The merger also brought Integrilin (
599:
591:
519:
325:
A merger with Leukosite in 1999 brought the company its first drug close-to-market,
583:
357:
298:
950:
350:
571:
549:
302:
218:
356:
In May 2003 Velcade was launched for the treatment of relapsed and refractory
964:
595:
523:
countries, at least 85,000 patients have been treated with Velcade globally.
433:
259:
178:
148:
603:
338:
282:
642:"Millennium Pharmaceuticals to acquire COR Therapeutics in $ 2 billion d"
274:
618:"Millennium to acquire Cambridge Discovery Chemistry for L35 million -"
365:
290:
200:
138:
518:
Pharmaceutical Research & Development. Takeda is responsible for
297:) through clinical trials to approval for treatment of patients with
787:"Six years and $ 8.8B later, Takeda is ditching the Millennium name"
32:
490:
342:
278:
270:
587:
330:
326:
294:
234:
508:
840:"Takeda announces voluntary withdrawal of lung cancer therapy"
495:
The first oral proteasome inhibitor to treat multiple myeloma
273:, development and commercialization activities focused in two
313:- with the name being simplified to Takeda Oncology in 2013.
940:
514:
Velcade was co-developed by Millennium Pharmaceuticals. and
372:
301:
by the U.S. FDA, but has a growing clinical development
690:"Schering-Plough buys Millennium's stake in heart drug"
666:"Millennium Pharmaceuticals Acquires Cor Therapeutics"
349:, into the Millennium fold. Millennium partnered with
57:. Unsourced material may be challenged and removed.
716:"UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
962:
813:"Takeda will finally drop the name 'Millennium'"
986:Pharmaceutical companies of the United States
991:Health care companies based in Massachusetts
981:Biotechnology companies of the United States
976:Pharmaceutical companies established in 1993
996:Companies based in Cambridge, Massachusetts
971:Biotechnology companies established in 1993
360:– a cancer of the blood. At the time, the
1011:American subsidiaries of foreign companies
864:
762:"The New Science Behind Medical Investing"
254:) is a biopharmaceutical company based in
117:Learn how and when to remove this message
810:
542:
311:Millennium: The Takeda Oncology Company
14:
963:
865:Kansteiner, Fraiser (3 October 2023).
759:
289:It is particularly known for bringing
834:
832:
784:
742:. Millennium Corporate Communications
538:
536:
569:
262:. It is a fully owned subsidiary of
55:adding citations to reliable sources
26:
572:"Millennium mergers bring pipeline"
24:
829:
533:
25:
1032:
934:
785:Garde, Damian (8 December 2014).
545:"Shift Seen Atop Takeda Oncology"
362:U.S. Food and Drug Administration
341:) Injection, an intravenous anti-
956:Article from the Washington Post
811:Seiffert, Don (8 October 2014).
31:
905:
884:
858:
804:
778:
42:needs additional citations for
753:
732:
708:
682:
658:
634:
610:
563:
543:Pollack, Andrew (2005-06-29).
345:drug for patients with severe
13:
1:
1016:2008 mergers and acquisitions
1006:Takeda Pharmaceutical Company
526:
399:
305:of other product candidates.
224:Takeda Pharmaceutical Company
191:Christophe Bianchi, President
570:Dove, Alan (December 1999).
7:
1021:Biopharmaceutical companies
390:
10:
1037:
951:Takeda Acquires Millennium
416:
316:
252:Millennium Pharmaceuticals
18:Millennium Pharmaceuticals
412:
409:
406:
403:
400:
229:
217:
207:
195:
185:
174:
166:
158:
144:
134:
646:www.thepharmaletter.com
622:www.thepharmaletter.com
347:cardiovascular diseases
1001:Life sciences industry
892:"FDA Approves VELCADE"
153:Pharmaceutical Company
516:Johnson & Johnson
438:Johnson & Johnson
410:Date Approved in USA
264:Takeda Pharmaceutical
576:Nature Biotechnology
51:improve this article
817:www.bizjournals.com
470:brentuximab vedotin
397:
209:Number of employees
131:
760:Willoughby, Jack.
432:Ortho Biotech and
396:Product Portfolio
395:
269:Takeda Oncology's
129:
946:The Velcade Three
520:commercialization
504:
503:
436:, members of the
245:
244:
127:
126:
119:
101:
66:"Takeda Oncology"
16:(Redirected from
1028:
941:Official website
928:
927:
925:
923:
909:
903:
902:
900:
899:
888:
882:
881:
879:
877:
862:
856:
855:
853:
851:
846:. 2 October 2023
836:
827:
826:
824:
823:
808:
802:
801:
799:
797:
782:
776:
775:
773:
772:
757:
751:
750:
748:
747:
736:
730:
729:
727:
726:
712:
706:
705:
703:
701:
686:
680:
679:
677:
676:
662:
656:
655:
653:
652:
638:
632:
631:
629:
628:
614:
608:
607:
567:
561:
560:
558:
557:
540:
398:
394:
358:multiple myeloma
299:multiple myeloma
241:
238:
236:
132:
128:
122:
115:
111:
108:
102:
100:
59:
35:
27:
21:
1036:
1035:
1031:
1030:
1029:
1027:
1026:
1025:
961:
960:
937:
932:
931:
921:
919:
911:
910:
906:
897:
895:
890:
889:
885:
875:
873:
863:
859:
849:
847:
838:
837:
830:
821:
819:
809:
805:
795:
793:
783:
779:
770:
768:
758:
754:
745:
743:
738:
737:
733:
724:
722:
714:
713:
709:
699:
697:
688:
687:
683:
674:
672:
664:
663:
659:
650:
648:
640:
639:
635:
626:
624:
616:
615:
611:
568:
564:
555:
553:
541:
534:
529:
393:
351:Schering-Plough
319:
248:Takeda Oncology
237:.takedaoncology
233:
210:
203:) for injection
188:
181:, United States
130:Takeda Oncology
123:
112:
106:
103:
60:
58:
48:
36:
23:
22:
15:
12:
11:
5:
1034:
1024:
1023:
1018:
1013:
1008:
1003:
998:
993:
988:
983:
978:
973:
959:
958:
953:
948:
943:
936:
935:External links
933:
930:
929:
904:
883:
857:
828:
803:
791:Fierce Biotech
777:
752:
731:
707:
696:. 24 July 2005
694:Fierce Biotech
681:
657:
633:
609:
562:
550:New York Times
531:
530:
528:
525:
502:
501:
499:
498:November 2015
496:
493:
488:
482:
481:
478:
475:
472:
467:
461:
460:
457:
454:
451:
448:
442:
441:
430:
427:
424:
421:
415:
414:
411:
408:
405:
402:
392:
389:
318:
315:
243:
242:
231:
227:
226:
221:
215:
214:
213:1200 (approx.)
211:
208:
205:
204:
197:
193:
192:
189:
186:
183:
182:
176:
172:
171:
168:
164:
163:
160:
156:
155:
146:
142:
141:
136:
125:
124:
39:
37:
30:
9:
6:
4:
3:
2:
1033:
1022:
1019:
1017:
1014:
1012:
1009:
1007:
1004:
1002:
999:
997:
994:
992:
989:
987:
984:
982:
979:
977:
974:
972:
969:
968:
966:
957:
954:
952:
949:
947:
944:
942:
939:
938:
918:
914:
908:
893:
887:
872:
871:Fierce Pharma
868:
861:
845:
841:
835:
833:
818:
814:
807:
792:
788:
781:
767:
763:
756:
741:
735:
721:
717:
711:
695:
691:
685:
671:
670:Bloomberg.com
667:
661:
647:
643:
637:
623:
619:
613:
605:
601:
597:
593:
589:
588:10.1038/70687
585:
581:
577:
573:
566:
552:
551:
546:
539:
537:
532:
524:
521:
517:
512:
510:
500:
497:
494:
492:
489:
487:
484:
483:
479:
476:
473:
471:
468:
466:
463:
462:
458:
455:
452:
449:
447:
444:
443:
439:
435:
434:Janssen-Cilag
431:
428:
425:
422:
420:
417:
404:Drug Name(s)
388:
384:
380:
376:
374:
369:
367:
363:
359:
354:
352:
348:
344:
340:
334:
332:
328:
323:
314:
312:
306:
304:
300:
296:
293:(marketed as
292:
287:
284:
280:
276:
272:
267:
265:
261:
260:Massachusetts
257:
253:
249:
240:
232:
228:
225:
222:
220:
216:
212:
206:
202:
198:
194:
190:
184:
180:
179:Cambridge, MA
177:
173:
169:
165:
161:
157:
154:
150:
149:Biotechnology
147:
143:
140:
137:
133:
121:
118:
110:
107:February 2009
99:
96:
92:
89:
85:
82:
78:
75:
71:
68: –
67:
63:
62:Find sources:
56:
52:
46:
45:
40:This article
38:
34:
29:
28:
19:
920:. Retrieved
916:
907:
896:. Retrieved
886:
874:. Retrieved
870:
860:
848:. Retrieved
843:
820:. Retrieved
816:
806:
794:. Retrieved
790:
780:
769:. Retrieved
765:
755:
744:. Retrieved
734:
723:. Retrieved
719:
710:
698:. Retrieved
693:
684:
673:. Retrieved
669:
660:
649:. Retrieved
645:
636:
625:. Retrieved
621:
612:
582:(12): 1151.
579:
575:
565:
554:. Retrieved
548:
513:
505:
485:
464:
450:mifamurtide
445:
418:
385:
381:
377:
370:
355:
339:eptifibatide
335:
324:
320:
310:
307:
288:
283:inflammation
268:
251:
250:(originally
247:
246:
175:Headquarters
135:Company type
113:
104:
94:
87:
80:
73:
61:
49:Please help
44:verification
41:
720:www.sec.gov
477:10-31-2012
456:March 2009
429:05-13-2003
423:bortezomib
407:Indication
401:Brand Name
275:therapeutic
965:Categories
922:29 October
898:2008-03-05
822:2024-01-19
796:19 January
771:2024-01-08
746:2008-03-05
725:2024-01-19
700:19 January
675:2024-01-19
651:2024-01-19
627:2024-01-19
556:2008-02-23
527:References
366:proteasome
291:bortezomib
201:bortezomib
187:Key people
139:Subsidiary
77:newspapers
876:8 January
850:8 January
596:1546-1696
256:Cambridge
199:Velcade (
604:10585700
491:Ixazomib
465:ADCETRIS
413:Partner
391:Products
343:platelet
303:pipeline
279:oncology
271:research
196:Products
145:Industry
844:Reuters
766:barrons
486:NINLARO
419:VELCADE
331:Genzyme
327:Campath
317:History
295:Velcade
277:areas:
230:Website
167:Defunct
159:Founded
91:scholar
917:Takeda
602:
594:
509:people
446:MEPACT
219:Parent
93:
86:
79:
72:
64:
894:. FDA
98:JSTOR
84:books
924:2017
878:2024
852:2024
798:2024
702:2024
600:PMID
592:ISSN
459:N/A
373:sNDA
281:and
239:.com
162:1993
70:news
584:doi
235:www
170:N/A
53:by
967::
915:.
869:.
842:.
831:^
815:.
789:.
764:.
718:.
692:.
668:.
644:.
620:.
598:.
590:.
580:17
578:.
574:.
547:.
535:^
333:.
266:.
258:,
151:,
926:.
901:.
880:.
854:.
825:.
800:.
774:.
749:.
728:.
704:.
678:.
654:.
630:.
606:.
586::
559:.
120:)
114:(
109:)
105:(
95:·
88:·
81:·
74:·
47:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
